Skip to content

Dr Per Lundin

Co-Founder and Chief Business Officer

Per has over 10 years of experience in advising, founding and leading biotech companies developing ground breaking therapies. Per developed and structured the IP and technology portfolio that formed the basis for the founding and £10m Series A financing of Evox and has acted as the company’s Chief Operating Officer since inception. Prior to founding Evox, Per co-founded and served as Chief Executive and Board member of IsletOne Therapeutics, a clinical-stage cell therapy company developing a proprietary mesenchymal stromal cell therapy for the treatment of acute respiratory distress syndrome and autoimmunity. Previously, Per managed a European business development channel for Thomson Reuters IP & Science and before that qualified as a European Patent Attorney in the biotech practice of one of the largest European IP law firms, advising clients on matters ranging from innovation strategy to commercialisation. He started his career as a Research Scientist with Apollo Life Sciences working on nanoparticle drug delivery. Per earned his Ph.D. at the Karolinska Institute, holds an MSc in Biotechnology Engineering, and an MBA from Stockholm University School of Business.

Dr Per Lundin